卡巴他赛与177Lu-PSMA放射性药物治疗转移性去势抵抗性前列腺癌的真实世界比较
基于FRAMCAP数据库373例mCRPC患者,比较卡巴他赛与177Lu-PSMA治疗的疗效。177Lu-PSMA组中位PFS显著优于卡巴他赛组(13.4个月 vs 7.1个月,P<0.001),多因素校正后HR为0.38(P<0.001)。总生存方面,卡巴他赛、177Lu-PSMA及两者联合治疗的中位OS分别为14.7、16.5和29.6个月(P<0.01)。
要点
- 177Lu-PSMA组中位PFS为13.4个月,显著优于卡巴他赛组的7.1个月(P<0.001)。
- 多因素校正后177Lu-PSMA较卡巴他赛的HR为0.38(P<0.001)。
- 卡巴他赛、177Lu-PSMA及联合治疗的中位OS分别为14.7、16.5和29.6个月(P<0.01)。
核心结论
- 在真实世界环境中,177Lu-PSMA较卡巴他赛化疗提供显著更好的PFS和定性更好的OS率。
- 根据欧洲药品管理局的批准,作者认为177Lu-PSMA应被视为晚期mCRPC患者的有价值治疗选择。
研究设计与样本
- 基于FRAMCAP数据库的真实世界比较研究,共纳入373例mCRPC患者。
- 14%接受卡巴他赛,65%接受177Lu-PSMA,21%两者均接受。
- 敏感性分析针对二至四线mCRPC治疗,以近似当前III期患者选择标准。
主要发现
- 177Lu-PSMA组患者显著年长于卡巴他赛组(中位72岁 vs 66岁,P<0.01)。
- 177Lu-PSMA组ECOG评分≥2的比例为12%,卡巴他赛组为5.0%(P=0.1)。
- PSA下降≥50%的比例:177Lu-PSMA组为32%,卡巴他赛组为0%。
- 中位PFS:177Lu-PSMA组13.4个月 vs 卡巴他赛组7.1个月(P<0.001),多因素校正后HR为0.38(P<0.001)。
- 中位OS:卡巴他赛组14.7个月 vs 177Lu-PSMA组16.5个月 vs 两者联合组29.6个月(P<0.01)。
关键数值与推荐
- PSA下降≥50%:177Lu-PSMA组32% vs 卡巴他赛组0%。
- 中位PFS:177Lu-PSMA组13.4个月 vs 卡巴他赛组7.1个月(P<0.001)。
- 多因素校正HR:0.38(P<0.001),比较177Lu-PSMA与卡巴他赛。
- 中位OS:卡巴他赛组14.7个月 vs 177Lu-PSMA组16.5个月 vs 联合组29.6个月(P<0.01)。
临床怎么用
- 作者认为,根据欧洲药品管理局的批准,177Lu-PSMA应被视为晚期mCRPC患者的有价值治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. Methods: We relied on the FRAMCAP database and compared cabazitaxel versus 177Lu-PSMA therapy in mCRPC patients regarding progression-free survival (PFS) and overall survival (OS). Sensitivity analyses addressed second- to fourth-line mCRPC treatment to approximate current phase III patient selection criteria. Results: Of 373 patients, 14% received cabazitaxel, 65% received 177Lu-PSMA, and 21% received both. Patients undergoing 177Lu-PSMA therapy were significantly older than cabazitaxel patients (median, 72 y vs. 66 y; P < 0.01), and a higher proportion had an Eastern Cooperative Oncology Group score of 2 or more (12% vs. 5.0%, P = 0.1). Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for 177Lu-PSMA versus cabazitaxel. In outcome analyses, significant superior median PFS was observed for 177Lu-PSMA versus cabazitaxel (13.4 mo vs. 7.1 mo, P < 0.001), even after multivariable adjustment (hazard ratio, 0.38; P < 0.001). Regarding OS, rates also significantly differed, with median OS of 14.7 mo versus 16.5 mo versus 29.6 mo for cabazitaxel versus 177Lu-PSMA versus both treatments (P < 0.01). In sensitivity analyses of second- to fourth-line mCRPC treatment, PFS rates and median OS rates for cabazitaxel versus 177Lu-PSMA versus both therapies qualitatively remained the same as for the entire cohort. Conclusion: In a real-world setting, 177Lu-PSMA provides significantly better PFS and qualitatively better OS rates than does cabazitaxel chemotherapy and should therefore be considered a valuable treatment option for advanced mCRPC patients according to the European Medicines Agency approval.
引用
- Wenzel M, Koll F, Hoeh B, et al. Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025. PMID: 39542702. doi:10.2967/jnumed.124.268807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。